{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T17:17:06Z","timestamp":1788628626298,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["NIH\/NCI 5R01CA233585 \u2013 05"],"award-info":[{"award-number":["NIH\/NCI 5R01CA233585 \u2013 05"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"DOI":"10.1038\/s41391-026-01150-3","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:41:12Z","timestamp":1788568872000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer"],"prefix":"10.1038","author":[{"given":"Christopher","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0919-9864","authenticated-orcid":false,"given":"Matthew","family":"Labriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0998-323X","authenticated-orcid":false,"given":"Clara","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-2951","authenticated-orcid":false,"given":"Pedro C.","family":"Barata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-3745","authenticated-orcid":false,"given":"Frank Cameron","family":"Cackowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6925-3095","authenticated-orcid":false,"given":"Amanda","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-7963","authenticated-orcid":false,"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Asim","family":"Bilen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kilari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4371-572X","authenticated-orcid":false,"given":"Laura S.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Garje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-8668","authenticated-orcid":false,"given":"Vadim S.","family":"Koshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5990-298X","authenticated-orcid":false,"given":"Tanya B.","family":"Dorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5510-0661","authenticated-orcid":false,"given":"Michael Thomas","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0356-8796","authenticated-orcid":false,"given":"Zachery R.","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra O.","family":"Sokolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2653-4110","authenticated-orcid":false,"given":"Catherine H.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-1754","authenticated-orcid":false,"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,5]]},"reference":[{"key":"1150_CR1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10354-015-0381-6","volume":"165","author":"G Hamilton","year":"2015","unstructured":"Hamilton G, Rath B. Smoking, inflammation and small cell lung cancer: recent developments. Wien Medizinische Wochenschr. 2015;165:379\u201386. https:\/\/doi.org\/10.1007\/s10354-015-0381-6.","journal-title":"Wien Medizinische Wochenschr"},{"key":"1150_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1056\/nejm198509053131001","volume":"313","author":"SM Lesko","year":"1985","unstructured":"Lesko SM, Rosenberg L, Kaufman DW, Helmrich SP, Miller DR, Strom B, et al. Cigarette smoking and the risk of endometrial cancer. N Engl J Med. 1985;313:593\u20136. https:\/\/doi.org\/10.1056\/nejm198509053131001.","journal-title":"N Engl J Med"},{"key":"1150_CR3","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/bjc.2012.520","volume":"108","author":"S Rohrmann","year":"2013","unstructured":"Rohrmann S, Linseisen J, Allen N, Bueno-de-mesquita H, Johnsen N, Tj\u00f8nneland A, et al. Smoking and the risk of prostate cnacer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer. 2013;108:708\u201314.","journal-title":"Br J Cancer"},{"key":"1150_CR4","doi-asserted-by":"crossref","unstructured":"Ordonez-Mena JM, Schottker B, Mons U, Jenab M, Freisling H, Bueo-de-Mesquita B, et al. Quantification of the smoking-associted cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium. BMC Med. 2016;14:62.","DOI":"10.1186\/s12916-016-0607-5"},{"key":"1150_CR5","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1158\/1055-9965.EPI-09-0252","volume":"18","author":"JL Watters","year":"2009","unstructured":"Watters JL, Park Y, Hollenbeck A, Schatzkin A, Albanes DE, et al. Cigarette smoking and prostate cancer in prospective US cohort study. Cancer Epidemiol Biomark Prev. 2009;18:2427\u201335.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1150_CR6","doi-asserted-by":"crossref","unstructured":"Moreira DM, Aronson WJ, Terris MK, Kane C, Amling C, Cooperberg M, et al. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy. Cancer. 2013;120:197\u2013204.","DOI":"10.1002\/cncr.28423"},{"key":"1150_CR7","doi-asserted-by":"crossref","unstructured":"Foerster B, Pozo C, Abufaraj M, Mari A, Kimura S, D\u2019Andrea D, et al. Association of smoking status with recurrence, metastasis, and mortality among patients with localized prostate cancer undergoing prostatectomy or radiotherapy: a systematic review and meta-analysis. JAMA Oncol. 2018;4:953\u201361.","DOI":"10.1001\/jamaoncol.2018.1071"},{"key":"1150_CR8","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1001\/jama.2011.879","volume":"305","author":"SA Kenfield","year":"2011","unstructured":"Kenfield SA, Stampfer MJ, Chan JM, et al. Smoking and prostate cancer survival and recurrence. JAMA. 2011;305:2548\u201355.","journal-title":"JAMA"},{"key":"1150_CR9","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1002\/cncr.30045","volume":"122","author":"IM Shui","year":"2016","unstructured":"Shui IM, Wong CJ, Zhao S, Kolb S, Ebot E, Geybels M, et al. Prostate tumor DNA methylation is associated with cigarette smoking and averse prostate cancer outcomes. Cancer. 2016;122:2168\u201377.","journal-title":"Cancer"},{"key":"1150_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George J, Lim JS, Jang SJ, Cun Y, Ozreti\u0107 L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524:47\u201353.","journal-title":"Nature"},{"key":"1150_CR11","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/ng.2405","volume":"44","author":"CM Rudin","year":"2012","unstructured":"Rudin CM, Durinck S, Stawiski EW, Poirier J, Modrusan Z, Shames D, et al. Comprehensive genomic analysis identifies SOX2 as frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44:1111\u20136.","journal-title":"Nat Genet"},{"key":"1150_CR12","doi-asserted-by":"crossref","unstructured":"Su S, Zou JJ, Zeng YY, Cen WC, Zhou W, Liu Y, et al. Tumor mutational burden and genomic alterations in Chinese small cell lung cancer measure by whole-exome sequencing. Biomed Res Int. 2019;2019:6096350.","DOI":"10.1155\/2019\/6096350"},{"key":"1150_CR13","doi-asserted-by":"publisher","unstructured":"Oh MS, Garon E, Lisberg A, Cummings A, Barett A, Ashok A, et al. Brief report: the genomic landscape of small cell lung cancer in never-smoking patients. Clin Lung Cancer. 2025;26:434\u20139. https:\/\/doi.org\/10.1016\/j.cllc.2025.03.011.","DOI":"10.1016\/j.cllc.2025.03.011"},{"key":"1150_CR14","doi-asserted-by":"crossref","unstructured":"Chen R, Dong X, Gleave M. Molecular model for neuroendocrine prostate cancer progression. BJUI. 2018;122:560\u201370.","DOI":"10.1111\/bju.14207"},{"key":"1150_CR15","first-page":"8","volume":"76","author":"GK Hubbard","year":"2015","unstructured":"Hubbard GK, Mutton LN, Khalili M, McMullin RP, Hicks JL, Bianchi-Frias D, et al. Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer. Cancer Res. 2015;76:8\u201311.","journal-title":"Cancer Res"},{"key":"1150_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487\u201395.","journal-title":"Cancer Discov"},{"key":"1150_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1593\/neo.121550","volume":"15","author":"JM Mosquera","year":"2013","unstructured":"Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagwa ST, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia. 2013;15:1\u201310.","journal-title":"Neoplasia"},{"key":"1150_CR18","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41391-021-00433-1","volume":"25","author":"VS Koshkin","year":"2022","unstructured":"Koshkin VS, Patel VG, Ali A, Bilen MA, Ravindranathan D, Park JJ, et al. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer Prostatic Dis. 2022;25:388\u201396.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1150_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamainternmed.2020.8360","volume":"181","author":"Lowe","year":"2021","unstructured":"Lowe, Zein K, Hatipoglu J, et al. Association of smoking and cumulative pack-year exposure with COVID-19 outcomes in the cleveland clinic covid-19 registry. JAMA Intern Med. 2021;181:709. https:\/\/doi.org\/10.1001\/jamainternmed.2020.8360.","journal-title":"JAMA Intern Med"},{"key":"1150_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ctrv.2018.07.001","volume":"70","author":"E Darcey","year":"2018","unstructured":"Darcey E, Boyle T. Tobacco smoking and survival after a prostate cancer diagnosis: a systematic review and meta-analysis. Cancer Treat Rev. 2018;70:30\u201340. https:\/\/doi.org\/10.1016\/j.ctrv.2018.07.001.","journal-title":"Cancer Treat Rev"},{"key":"1150_CR21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.5173\/ceju.2024.31.R1","volume":"77","author":"AM Garc\u00eda-Cano-Fern\u00e1ndez","year":"2024","unstructured":"Garc\u00eda-Cano-Fern\u00e1ndez AM, P\u00e1ez Borda \u00c1, Llanes Gonz\u00e1lez L, Luj\u00e1n Gal\u00e1n M. Value of baseline PSA in predicting prostate cancer diagnosis and death. Spanish arm of the European Randomized Study of Screening for Prostate Cancer. Cent Eur J Urol. 2024;77:383\u20138. https:\/\/doi.org\/10.5173\/ceju.2024.31.R1.","journal-title":"Cent Eur J Urol"},{"key":"1150_CR22","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.urolonc.2014.01.004","volume":"ume 32","author":"C Rusthoven","year":"2014","unstructured":"Rusthoven C, Carlson JA, Waxweiler TV, Yeh N, Raben D, Flaig TW, et al. The prognostic significance of Gleason scores in metastatic prostate cancer. Urol Oncol: Semin Original Investig. 2014;ume 32:707\u201313.","journal-title":"Urol Oncol: Semin Original Investig"},{"key":"1150_CR23","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1001\/jama.2011.879","volume":"305","author":"SA Kenfield","year":"2011","unstructured":"Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA. 2011;305:2548\u201355.","journal-title":"JAMA"},{"key":"1150_CR24","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/jnci\/djr124","volume":"103","author":"CE Joshu","year":"2011","unstructured":"Joshu CE, Mondul AM, Meinhold CL, Humphreys EB, Han M, Walsh PC, et al. Cigarette smoking and prostate cancer recurrence after prostatectomy. J Natl Cancer Inst. 2011;103:835\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"1150_CR25","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.eururo.2015.05.038","volume":"68","author":"M Rieken","year":"2015","unstructured":"Rieken M, Shariat SF, Kluth LA, Fajkovic H, Rink M, Karakiewicz P, et al. Association of cigarette smoking and smoking cessation with biochemical recurrence of prostate cancer in patients treated with radical prostatectomy. Eur Urol. 2015;68:949\u201356.","journal-title":"Eur Urol"},{"key":"1150_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.molcel.2009.09.022","volume":"36","author":"M Zhuang","year":"2009","unstructured":"Zhuang M, Calabrese MF, Liu J, Waddell MB, Nourse A, Hammel M, et al. Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol Cell. 2009;36:39\u201350. https:\/\/doi.org\/10.1016\/j.molcel.2009.09.022.","journal-title":"Mol Cell"},{"key":"1150_CR27","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ng.2279","volume":"44","author":"CE Barbieri","year":"2012","unstructured":"Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44:685\u2013U107. https:\/\/doi.org\/10.1038\/ng.2279.","journal-title":"Nat Genet"},{"key":"1150_CR28","doi-asserted-by":"crossref","unstructured":"Wang ZW, Song YZ, Ye MM, Dai XM, Zhu XQ, Wei WY. The diverse roles of SPOP in prostate cancer and kidney cancer. Nat Rev Urol. 2020;17:339\u201350","DOI":"10.1038\/s41585-020-0314-z"},{"key":"1150_CR29","doi-asserted-by":"publisher","first-page":"14386","DOI":"10.1073\/pnas.1908767116","volume":"116","author":"CD Geng","year":"2019","unstructured":"Geng CD, He B, Xu LM, Barbieri CE, Eedunuri VK, Chew SA, et al. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci USA. 2019;116:14386\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1150_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.1250255","volume":"346","author":"J-PP Theurillat","year":"2014","unstructured":"Theurillat J-PP, Udeshi ND, Errington WJ, Svinkina T, Baca SC, Pop M, et al. UBIQUITYLOME analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science. 2014;346:85\u20139. https:\/\/doi.org\/10.1126\/science.1250255.","journal-title":"Science"},{"key":"1150_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18632\/oncotarget.27859","volume":"12","author":"J Ko","year":"2021","unstructured":"Ko J, Meyer AN, Haas M, Donoghue DJ. Characterization of FGFR signaling in prostate cancer stem cells and inhibition via TKI treatment. Oncotarget. 2021;12:22\u201336.","journal-title":"Oncotarget"},{"key":"1150_CR32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/wdev.176","volume":"4","author":"DM Ornitz","year":"2015","unstructured":"Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4:215\u201366. https:\/\/doi.org\/10.1002\/wdev.176.","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"1150_CR33","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/bjc.2011.367","volume":"105","author":"K Armstrong","year":"2011","unstructured":"Armstrong K, Ahmad I, Kalna G, Tan SS, Edwards J, Robson CN, et al. Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer. Br J Cancer. 2011;105:1362\u20139. https:\/\/doi.org\/10.1038\/bjc.2011.367.","journal-title":"Br J Cancer"},{"key":"1150_CR34","doi-asserted-by":"publisher","unstructured":"Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. \u201cAndrogen receptor pathway-independent prostate cancer is sustained through FGF signaling\u201d.Cancer Cell. 2017;32. https:\/\/doi.org\/10.1016\/j.ccell.2017.09.003.","DOI":"10.1016\/j.ccell.2017.09.003"},{"key":"1150_CR35","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41416-025-02944-3","volume":"132","author":"A Hartley","year":"2025","unstructured":"Hartley A, Galbraith LCA, Shaw R, Tibbo A, Veeratterapillay R, Wilson L, et al. Loss of ARID1A accelerates prostate tumourigenesis with a proliferative collagen-poor phenotype through co-operation with AP1 subunit cFos. Br J Cancer. 2025;132:502\u201312.","journal-title":"Br J Cancer"},{"key":"1150_CR36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nrurol.2018.22","volume":"15","author":"AH Davies","year":"2018","unstructured":"Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol. 2018;15:271\u201386. https:\/\/doi.org\/10.1038\/nrurol.2018.22.","journal-title":"Nat Rev Urol"},{"key":"1150_CR37","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/ng.2256","volume":"44","author":"C Guichard","year":"2012","unstructured":"Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Ben Maad I, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012;44:694\u20138. https:\/\/doi.org\/10.1038\/ng.2256.","journal-title":"Nat Genet"},{"key":"1150_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-01003-9","volume":"23","author":"Y Yamada","year":"2021","unstructured":"Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep. 2021;23:15.","journal-title":"Curr Oncol Rep"},{"key":"1150_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.addicn.2023.100079","volume":"6","author":"F Fang","year":"2023","unstructured":"Fang F, Andersen AM, Philibert R, Hancock DB. Epigenetic biomarkers for smoking cessation. Addict Neurosci. 2023;6:100079. https:\/\/doi.org\/10.1016\/j.addicn.2023.100079.","journal-title":"Addict Neurosci"},{"key":"1150_CR40","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1159\/000509427","volume":"43","author":"PR Von Kroge","year":"2020","unstructured":"Von Kroge PR, Bokemeyer F, Ghandili S, Bokemeyer C, Seidel C. The impact of smoking cessation and continuation on recurrence and survival in patients with head and neck cancer: a systematic review of the literature. Oncol Res Treat. 2020;43:549\u201358. https:\/\/doi.org\/10.1159\/000509427.","journal-title":"Oncol Res Treat"},{"key":"1150_CR41","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/bjc.2017.179","volume":"117","author":"C Koshiaris","year":"2017","unstructured":"Koshiaris C, Aveyard P, Oke J, Ryan R, Szatkowski L, Stevens R, et al. Smoking cessation and survival in lung, upper aero-digestive tract and Bladder Cancer: Cohort study. Br J Cancer. 2017;117:1224\u201332. https:\/\/doi.org\/10.1038\/bjc.2017.179.","journal-title":"Br J Cancer"},{"key":"1150_CR42","doi-asserted-by":"publisher","unstructured":"J\u00e4rbur E, Holmberg E, Bj\u00f6rk-Eriksson T, Bratt O, Godtman RA. \u201cAssociations between socioeconomic factors and PSA testing in a population-based organised testing programme and Routine Healthcare: a register-based study of 50-year-old men\u201d. BMJ Oncol. 2024;3. https:\/\/doi.org\/10.1136\/bmjonc-2024-000400.","DOI":"10.1136\/bmjonc-2024-000400"},{"key":"1150_CR43","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/aje\/kww084","volume":"184","author":"TP Kilpel\u00e4inen","year":"2016","unstructured":"Kilpel\u00e4inen TP, Talala K, Raitanen J, Taari K, Kujala P, Tammela TLJ, et al. Prostate cancer and socioeconomic status in the finnish randomized study of screening for prostate cancer. Am J Epidemiol. 2016;184:720\u201331. https:\/\/doi.org\/10.1093\/aje\/kww084.","journal-title":"Am J Epidemiol"},{"key":"1150_CR44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/21681805.2017.1411392","volume":"52","author":"J Hugosson","year":"2018","unstructured":"Hugosson J, Ansrud Godtman R, Carlsson SV, Aus G, Grenabo Bergdahl A, Lodding P, et al. Eighteen-Year follow-up of the g\u00f6teborg randomized population-based prostate cancer screening trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand J Urol. 2018;52:27\u201337. https:\/\/doi.org\/10.1080\/21681805.2017.1411392.","journal-title":"Scand J Urol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01150-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01150-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01150-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T17:02:32Z","timestamp":1788627752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01150-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,5]]},"references-count":44,"alternative-id":["1150"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01150-3","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,5]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AJA reports research support (to Duke) from the NIH\/NCI, PCF\/Movember, DOD, Astellas, Pfizer, Bayer, Janssen, BMS, AstraZeneca, Merck, Pathos, Amgen, Novartis. He reports consulting or advising relationships with Astellas, Pfizer, Bayer, Janssen, BMS, AstraZeneca, Merck, Forma, Celgene, Myovant, Exelixis, GoodRx, Novartis, Medscape, MJH, Z Alpha, and Telix. Dr. Alexandra O. Sokolova: Astra Zeneca: consulting, travel, research funds. Astellas: speaker. CELC-G: consulting. Regeneron: research funding. Novartis: research funding. RR. McKay: Ambrx, Arcus, AstraZeneca, Aveo, Bayer, Blue Earth Diagnostics, Boundless Bio, Bristol Myers Squibb, Calithera, Caris, Dendreon, Daiichi Sankyo, Eli Lilly, Eisai, Exelixis, Janssen, Merck, Myovant, Neomorph, Nimbus, Novartis, Pfizer, Sanofi, SeaGen, Sorrento Therapeutics, Telix, and Tempus. PC. Barata: Astellas; AstraZeneca; AVEO Oncology; Bayer; BMS; Dendreon; Eisai; EMD Serono; ESSA Pharma; Guardant Health; Ipsen; Caris Life Sciences; Exelixis; Janssen; Merck; Merus; MJH; Myovant; Novartis; Pfizer, Seattle Genetics; UroToday Equity: Luminate Medical. ZRR: AstraZeneca and Janssen; and research funding through the institution from AstraZeneca. CHM: Astra Zeneca to the institution. Consulting\/Advisory: Pfizer; Honorarium: Tempus. MTS: Sanofi, Fibrogen, Daiichi Sankyo, Novartis, Zenith Epigenetics, Eli Lilly, BMS, Merck, Immunomedics, Tmunity, SingalOne Bio, Epigenetix, Xencor, lncyte, Ambrx, Oric Pharmaceuticals, AstraZeneca, Janssen, Pfizer. CH: Johnson and Johnson, Astellas, Merck, Bayer, AstraZeneca, Pfzier\/Seagen, Taiho, Hengrui, Scholar Rock, Exelixis, Fujifilm, and Adcentrx, Genetech, Dendreon, Exelixis. TBD: Abbvie, Amgen, AstraZeneca and Consulting fees from Astellas, AstraZeneca, Bayer, Janssen, Novartis, Pfizer, Blue Earth, Foundation Medicine. DK: Astellas, Pfizer, Genentech, Exelixis, SOBI. Consulting fees from Pfizer, Bayer, Janssen, AstraZeneca, Myovant, Exelixis, Aveo oncology, Eisai, Aptitude, MJH and Integra Connect.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods in our study were performed in accordance with the relevant guidelines and regulations. This study was IRB and consent exempted by the Duke IRB given retrospective design and use of a centrally deidentified database at the University of Michigan (Protocol ID: Pro00104916).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}